Advances in the Treatment of Alzheimer Disease: Current Landscape and Future Directions

A panel of experts on Alzheimer disease provide insights on symptoms the patient might experience and the impact of the disease on patients, families, caregivers, and the health care system.

B. Joy Snider, MD, PhD, gives an overview of the pathophysiology of Alzheimer disease, highlighting recent advances in the field.

The panel provides an overview of genetic factors associated with Alzheimer disease and the genetic mutations that contribute to the pathophysiology of the disease.

The expert panel offers comprehensive insights on the patient journey for people with Alzheimer disease, highlighting symptoms, challenges, and the diagnostic process.

B. Joy Snider, MD, PhD, discusses the benefits of early diagnosis of Alzheimer disease and how it can impact the patient journey.

Focusing on the diagnosis of Alzheimer disease, the panel discusses key diagnostic criteria, testing practices, and the role of genetic testing.

The panel provides insights on the economic impact of advanced approaches for diagnosing Alzheimer disease, highlighting how payers approach increased costs.

Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.

Experts provide their perspectives on clinical factors taken into consideration when deciding on a treatment plan for a patient with Alzheimer disease.

A comprehensive discussion on the value of therapies for Alzheimer disease based on cost vs outcome, and unmet needs in the overall treatment landscape.

The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.

An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.

Experts discuss how payers can prepare for new treatments and plan adequate coverage for patients with Alzheimer disease.

Looking to the future of Alzheimer disease treatment, the panel discusses key takeaways on the evolving therapeutic landscape.